---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-115672"
form_type: "8-K"
ticker: "ELAN"
cik: "0001739104"
company_name: "Elanco Animal Health Inc"
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:09:02.144199+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Elanco Q3 revenue $1,028M, net loss $49M; cuts FY 2022 guidance on FX and macro headwinds

## Summary
- Q3 revenue down 9% reported (4% constant currency) to $1,028M; pet health fell 11%, farm animal down 7%.
- Reported EPS $(0.10); adjusted EPS $0.20 (up 5% YoY); adjusted EBITDA $205M (19.9% margin, +120bps).
- FY 2022 revenue guidance lowered to $4,385-4,430M (from $4,465-4,550M); adjusted EPS cut to $1.01-1.07 from $1.06-1.13.
- Net leverage ratio 5.2x; $170M gross debt reduction in Q3; cash flow from ops $189M vs $89M YoY.
- Pipeline: FDA submission for broad-spectrum parasiticide; SGLT-2 feline diabetes drug and parvovirus mAb expected approvals by early 2023.

## SEC filing metadata
- accession: 0001104659-22-115672
- form_type: 8-K
- ticker: ELAN
- cik: 0001739104
- company_name: Elanco Animal Health Inc
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739104/000110465922115672/0001104659-22-115672-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739104/000110465922115672/tm2229803d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-115672
- JSON: https://secwatch.observer/filing/0001104659-22-115672.json
- Plain text: https://secwatch.observer/filing/0001104659-22-115672.txt

## Key facts
- Earnings Releases
  Elanco Animal Health Inc reported the fiscal quarter ended September 30, 2022 results: revenue $1,028 million, net income Reported Net Loss of $49 million, EPS Reported EPS of $(0.10). Guidance lowered.
  - Period: the fiscal quarter ended September 30, 2022
  - Revenue: $1,028 million
  - Net income: Reported Net Loss of $49 million
  - EPS: Reported EPS of $(0.10)
  - Guidance: lowered
  - Result: reported results
  source text: Colleen Parr Dekker (317) 989-7011 or colleen.dekker@elancoah.com Elanco Animal Health Reports Third Quarter 2022 Results • Third Quarter 2022 Financial Results ◦ Revenue of $1,028 million ◦ Reported Net Loss of $49 million, Adjusted Net Income of $96 million ◦ Adjusted EBITDA of $205 million or 19.9% of Revenue ◦ Reported EPS of $(0.10), Adjusted EPS of $0.20 ◦
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739104/000110465922115672/0001104659-22-115672-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.